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NIH-12848 (NCGC00012848-02), a putative phosphatidylinos-
itol 5-phosphate 4-kinase γ (PI5P4Kγ ) inhibitor, was explored
as a tool for investigating this enigmatic, low activity, lipid
kinase. PI5P4K assays in vitro showed that NIH-12848 inhibited
PI5P4Kγ with an IC50 of approximately 1 μM but did not inhibit
the α and β PI5P4K isoforms at concentrations up to 100 μM. A
lack of inhibition of PI5P4Kγ ATPase activity suggested that
NIH-12848 does not interact with the enzyme’s ATP-binding
site and direct exploration of binding using hydrogen–deuterium
exchange (HDX)-MS (HDX-MS) revealed the putative PI5P-
binding site of PI5P4Kγ to be the likely region of interaction.
This was confirmed by a series of mutation experiments which
led to the identification of a single PI5P4Kγ amino acid residue
that can be mutated to its PI5P4Ks α and β homologue to render
PI5P4Kγ resistant NIH-12848 inhibition. NIH-12848 (10 μM)
was applied to cultured mouse principal kidney cortical collecting
duct (mpkCCD) cells which, we show, express PI5P4Kγ that
increases when the cells grow to confluence and polarize. NIH-
12848 inhibited the translocation of Na+ /K+ -ATPase to the
plasma membrane that occurs when mpkCCD cells grow to
confluence and also prevented reversibly their forming of ‘domes’
on the culture dish. Both these NIH-12848-induced effects were
mimicked by specific RNAi knockdown of PI5P4Kγ , but not that
of PI5P4Ks α or β. Overall, the data reveal a probable contribution
of PI5P4Kγ to the development and maintenance of epithelial
cell functional polarity and show that NIH-12848 is a potentially
powerful tool for exploring the cell physiology of PI5P4Ks.
Key words: phosphatidylinositol 5-phosphate (PI5P), phos-
phatidylinositol 5-phosphate 4-kinase (PI5P4K), phosphatidylin-
ositol 5-phosphate 4-kinase γ (PI5P4Kγ ).
INTRODUCTION
The phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are a
family consisting of three isoforms in mammals (α, β and γ ),
whose most probable function is currently believed to be the
regulation of the levels of their substrate, PI5P [1,2]. Although the
α and β isoforms have had some physiological and pathological
functions assigned to them, including in gene regulation [3,4],
stress responses [5], insulin signalling [6] and cancer [7,8],
PI5P4Kγ is hardly understood at all. It is apparently ubiquitously
expressed, but at very different levels between tissues, being
particularly high in epithelial cells of the thick ascending limb of
the kidney and collecting ducts cells [9] and in specific neurons
in brain [10]. It apparently has a vesicular localization [9,10],
may have a functional connection with Rho [11], shows a much
lower enzymatic activity in vitro than the other PI5P4K isoforms
[12] and can heterodimerize in vitro with PI5P4Kα [12] (note that
extensive heterodimerization between PI5P4Ks α and β has been
shown to occur in vivo [13,14]).
Specific inhibitors of enzymes can be useful tools in studying
their function and kinase inhibitors are among those that have
shown most promise as potential therapeutic agents. Recently,
the characterization of inhibitors for PI5P4Kα [15] and PI5P4Kβ
[16] have raised that hope for those isoforms, but the isoform
specificity of neither inhibitor has yet been established and so far
no such tools exist for PI5P4Kγ . Moreover, a challenge facing
any kinase inhibitor, the great majority of which interact with the
ATP-binding site of their target, is for it to have both sufficient
specificity (because all kinase ATP-binding sites show some
structural similarity) and potency (cellular concentrations of ATP
are in the millimolar range, so nanomolar affinity of an inhibitor
is often required for micromolar efficacy in a cell). The high
affinity and specificity of the phosphoinositide 3-kinase (PI3K)-δ
inhibitor PIK-39 that results from a remarkable induced fit into
the ATP-binding site of its target protein [17] is one example of
an ATP-binding site competitor that overcomes these issues. A
potential approach for increasing the kinase specificity is to look
for ATP-allosteric modulators, although in some cases (e.g. [18])
there are discrepancies between cell-based and isolated kinase
inhibitory assays, making difficult the finding of this kind of
inhibitor.
Herein, we report the characterization and use of a PI5P4Kγ -
specific inhibitor NIH-12848 (full designation NCGC00012848-
02), which we show interacts not with the ATP-binding site
but with the region where PI5P probably binds, including the
activation loop. We use the inhibitor to begin the first exploration,
in a kidney epithelial cell line, of the function of PI5P4Kγ .
Also, we show how we can mutate PI5P4Kγ so that it becomes
Abbreviations: HDX, hydrogen–deuterium exchange; HDX-MS, hydrogen-deuterium exchange mass spectrometry; mpkCCD, mouse principal kidney
cortical collecting duct; PI5P, phosphatidylinositol 5-phosphate; QT-PCR, quantitative PCR; TBP, TATA-box-binding protein; TCEP, tris carboxyl ethyl
phosphine; UPLC, ultra performance liquid chromatography; WT, wild-type.
1 These authors contributed equally to this study.
2 Present address: Department of Biochemistry and Microbiology, University of Victoria, 270a Petch Hall, Victoria, British Columbia, Canada
V8W 2Y2.
3 To whom correspondence should be addressed (email rfi20@cam.ac.uk).
c© The Authors Journal compilation c© 2015 Biochemical Society
360 J.H. Clarke and others
insensitive to NIH-12848, opening the possibility of chemical
biology to explore the functions of all three PI5P4Ks.
MATERIALS AND METHODS
Enzyme preparation and mutagenesis
Recombinant enzyme was prepared essentially as described
previously [12]. Protein from PIP4K2C (UniGene 6280511) or
associated mutants, cloned into the expression vector pGEX6P
(GE Healthcare) was expressed and purified from Escherichia
coli BL21(DE3). Cultures were induced with 0.4 mM IPTG
and probe-sonicated in the presence of protease inhibitors. GST
fusion proteins of PI5P4Kγ and PI5P4Kγ+, a mutant with
specific activity close to that of the active PI5P4Kα isoform
[12], were harvested by binding to glutathione sepharose beads
(GE Healthcare) and cleaved in situ with 50 units of PreScission
protease (GE Healthcare) for 4 h at 4 ◦C. Purity was confirmed by
SDS/PAGE and protein concentration determined by colorimetric
assay (Bio-Rad). Site-directed mutagenesis using the QuikChange
technique (Agilent Technologies) was used to generate clones
from which mutant forms of PI5P4Kγ and PI5P4Kγ + were
produced (for mutagenesis primers see Supplementary Table S1).
Biochemical assays
Lipid kinase assays were performed as described previously [13].
Dipalmitoyl-PI5P (DiC16–PI5P) was purchased from Echelon
Biosciences and after drying down in Eppendorf tubes was
sonicated for 3 × 30 s in a Decon Ultrasonics sonicating bath.
This lipid substrate (6 μM PI5P) and recombinant lipid kinase
were added to the reaction mixture (200 μl of final volume)
with 10 μCi [γ -32P]ATP and incubated at 30 ◦C for 10–60 min.
Lipids were extracted using an acidic phase-separation [19] and
separated by 1D thin layer chromatography (2.8:4:1:0.6 chlo-
roform:methanol:water:ammonia). Radiolabelled PtdIns(4,5)P2
spots were detected by autoradiography, extracted and counted
with Ultima Gold XR scintillant (Packard) on a LS6500
scintillation counter (Beckman Coulter). Intrinsic ATPase
activities of the enzymes were determined using the Transcreener
ADP2 fluorescence polarization method (BellBrook Labs). A
range of enzyme concentrations was assayed with ATP substrate
(100 μM ATP, 60 min incubation at 22 ◦C) and polarization units
(mP) were read using a PHERAstar Plus microplate reader
(BMG Labtech). Experimental values were interpolated from an
ADP/ATP utilization standard curve and plotted using non-linear
regression analysis with Prism 5.
Hydrogen–deuterium exchange MS
Hydrogen–deuterium exchange (HDX)-MS experiments were
performed according to previously published protocols [20,21].
In brief, HDX reactions were initiated in HDX buffer [20 mM
HEPES, pH 7.5, 50 mM NaCl, 2 mM Tris carboxyl ethyl
phosphine (TCEP)] by the addition of 98% 2H2O solution
(10 mM HEPES pH 7.5, 50 mM NaCl, 2 mM TCEP), to give
a final concentration of 78% 2H2O. Final protein concentrations
were 1 μM. For all reactions with inhibitor, there was a 10-fold
excess of inhibitor over protein and this was allowed to incubate
for 30 min on ice before initiation of HDX. Four time points
of exchange were carried out (3, 30 and 300 s at 23 ◦C and 3 s at
0 ◦C) and were terminated by the addition of a quench buffer (1 M
guanidine-HCl, 0.8% formic acid), followed by snap freezing
in liquid nitrogen. Samples were stored at − 80 ◦C until mass
analysis.
Measurement of deuterium incorporation
Protein samples were rapidly thawed and injected on to a UPLC
(ultra performance liquid chromatography) column immersed
in ice, as previously described [21]. The protein was run over
two immobilized pepsin columns in series (Applied Biosystems;
porosyme) at 200 μl/min for 3 min and collected over a van-guard
pre-column trap (Waters). The trap was subsequently eluted in
line with an Acquity 1.7 μm particle, 100 x 1 mm2 C18 UPLC
column (Waters), using a gradient of 5%–36% buffer B (buffer
A 0.1% formic acid, buffer B 100% acetonitrile) over 20 min.
Eluent from the column was injected on to a Xevo QTOF (Waters)
acquiring over a mass range from 350 to 1500 m/z, with an ESI
source operated at a temperature of 225 ◦C and a spray voltage of
2.5 kV.
Protein digestion, peptide identification and mass analysis
Peptide identification was done by running tandem MS/MS
experiments using a 3%–35% B gradient over 120 min with
a Xevo QTOF (Waters). This was supplemented with a 20 min
gradient separation to identify and correct the retention time for
all samples. The MS tolerance was set to 3 ppm with a MS/MS
tolerance at 0.1 Da. The resulting MS/MS datasets were analysed
with the Mascot search within Mascot distiller (Matrix Science).
All peptides with a Mascot score >15 were analysed using HD-
Examiner Software (Sierra Analytics). The full list of peptides
was then manually validated by searching a non-deuterated
protein sample’s MS scan to test for the correct m/z state and
check for the presence of overlapping peptides. Ambiguously
identified peptides were excluded from all subsequent analysis.
The first round of analysis and identification were performed
automatically by the HD-Examiner software, but all peptides
(deuterated and non-deuterated) were manually verified at every
state and time point for the correct charge state, m/z range,
presence of overlapping peptides and the expected retention time.
All HDX–MS results are presented as relative levels of deuterium
incorporation and no correction for back exchange is applied,
because no fully deuterated protein sample could be obtained.
Cell culture
Immortalized mouse cortical collecting duct (mpkCCD)
cells [22,23] were grown in defined medium [Dulbecco’s
Modified Eagle Medium (DMEM):Ham’s F12 1:1 (v/v), 60 nM
sodium selenate, 5 μg/ml transferrin, 2 mM glutamine, 50 nM
dexamethasone, 1 nM tri-iodothyronine, 10 ng/ml epidermal
growth factor, 5 μg/ml insulin, 20 mM D-glucose, 2% (v/v) fetal
calf serum and 20 mM HEPES, pH 7.4] at 37 ◦C in a 5% CO2,
95% air atmosphere. Medium was changed every 2 days and all
studies were performed on cells that had been grown on plastic
Petridishes or glass slides.
RNAi
Depletion of specific PI5P4K isoforms was achieved by
transfecting cells with siRNAs specific to each PI5P4K
isoform. The siRNAs were obtained from Thermo Scientific
Dharmacon (ON-TARGETplus SMART pool). Control siRNAs
were sequences that would not be recognized by any part of
the mouse genome. mpkCCD cells were plated at a density
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of 6 × 104 per well (24-well/plate) 1 day before transfection,
then were transfected with each siRNA at a final concentration
of 25 pmol/ml using DharmaFECT 1 Transfection Reagent
(Dharmacon). At 72-h post-transfection, a new round of
transfection was performed and the cells were cultured for another
48 h.
Morphological and immunocytochemical studies
Confluent cells grown on plastic Petridishes were examined
under an inverted microscope (Zeiss) equipped with phase-
contrast optics. Indirect immunofluorescence studies were
performed on confluent cells grown on glass slides fixed
with ice-cold methanol or 4% formaldehyde. Cells were
processed for immunofluorescence using anti-Na+ /K+ -ATPase
α-1 monoclonal antibody (Millipore) and anti-zona occludens-1
(anti-ZO-1) polyclonal antibodies (Millipore) and were examined
under a Leica confocal microscope.
Western blotting
Cells were grown to confluence, washed in cold PBS and lysed by
scraping them off in boiling Laemmli sample buffer containing
20 mM 2-mercaptoethanol. Lysate was boiled for 5 min and
viscosity was reduced by sonication using four bursts of 30 s each
with 15 s on ice between each sonication step. Lysate was boiled
as before and centrifuged at 20000 g for 5 min. The supernatant
was run on 10% polyacrylamide gels, transferred to nitrocellulose
membranes, blocked in TBS/0.05% Tween 20/5% non-fat dry
milk and probed with antibodies diluted in the same solution.
The following primary antibodies were used: polyclonal anti-
PI5P4Kγ 1:2500 [9], monoclonal anti-α tubulin 1:5000 (Sigma–
Aldrich). After washing in TBS/0.05% Tween and incubation
with secondary antibody, protein was detected by Super Signal
West Femto Maximum Sensitivity Substrate (Thermo Scientific).
QT (quantitative)-PCR
Cellular RNA was extracted with Trizol reagent (Invitrogen) and
1 ng was reverse transcribed with Superscript III and random
hexamers (Invitrogen). Quantification of gene expression of the
three PI5P4K isoforms was assessed by using TaqMan Gene
Expression Assays and TaqMan Gene Expression Master Mix
(Life Technologies), using TATA-box-binding protein (TBP) as
the reference gene.
RESULTS AND DISCUSSION
NIH-12848 is a specific PI5P4Kγ inhibitor
NIH-12848 (Figure 1) initially emerged as ‘compound 1’ from a
kinome profiling study, measuring its selectivity against a panel
of 460 kinases (see Supplementary Figure S3 in ref [24]). As
can be seen in the supporting information (Supplementary Table
S2), NIH-12848 was exquisitely selective for PI5P4Kγ , with
an apparent IC50 of 2–3 μM (Supplementary Figure S1). This
screen did not include PI5P4Kα (Supplementary Figure S2) and
to clarify the actions of NIH-12848 against PI5P4Ks we tested
it in PI5P4K assays using PI5P and 32P-γ -ATP as substrates
(see Materials and Methods). Under these conditions, PI5P4Kα
was not inhibited by 100 μM NIH-12848 (Supplementary Figure
S3A) and PI5P4Kβ showed a small but significant stimulation at
the same concentration (Supplementary Figure S3B), whereas
PI5P4Kγ was inhibited with an apparent IC50 of 3.3 μM
Figure 1 Structure of NIH-12848
Figure 2 Effect of inhibitor NIH-12848 on PI5P4Kγ activity
(A) Dose-response curve showing inhibition of PI5P4K activity over a range of inhibitor
concentrations (0.01–100 μM). Points represent a mean of five replicates and error bars
indicate +− S.E.M. (B) Effect of a range of inhibitor concentrations on intrinsic ATPase activity
of PI5P4Kγ . Bars represent percentage ATP conversion by PI5P4Kγ (1 μM) in the presence
of NIH-12848, in comparison with the indicated positive control (; 1μM PI5P4Kγ in the
absence of inhibitor). A negative control was also included (; inhibitor only, no enzyme). n =
3, error bars represent +− S.E.M.
(Figure 2), similar to the apparent Kd in the kinome profiling
(above).
Because PI5P4Kγ has a very low catalytic activity [12], these
assays use a final enzyme concentration of around 2.3 μM, so
it is possible that NIH-12848 is actually more potent and we
are, in part, titrating the enzyme protein. We therefore also
tested NIH-12848 on nanomolar levels of the PI5P4Kγ + mutant
[12], which has a 300-fold higher activity than wild–type (WT)
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Figure 3 Binding of NIH-12848 to PI5P4Kγ studied by HDX–MS
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PI5P4Kγ and we found the IC50 of NIH-12848 to be about 1 μM
(Supplementary Figure S3C). Below we show that the PI5P-
binding site is the likely site of interaction for NIH-12848 and
because the lipid PI5P does not have a precise concentration (not
least this depends on its physicochemical structure), the number
we deduce here can only be an empirical IC50, not an absolute K i.
NIH-12848 interacts with the PI5P-binding site on PI5P4Kγ
Most of the mutations introduced into PI5P4Kγ to create
PI5P4Kγ + [12] involve the changing of residues that bind or
stabilize ATP to the equivalent residues present in the much
more active PI5P4Kα. So the marked contrast in sensitivities to
NIH-12848 of PI5P4Kγ + compared with PI5P4Kα suggested
that NIH-12848 could be unusual among kinase inhibitors in
that it might not be interacting with the ATP-binding site. This
possibility was supported by an inability of NIH-12848 to inhibit
the intrinsic ATPase activity of PI5P4Kγ (Figure 2B) and by
the observation that including 100 μM ATP in assays using
PI5P4Kγ + (Km for ATP, 2 μM [12]) had only a small effect
on the ability of NIH-12848 to inhibit the enzyme near its
IC50 concentration: 2 μM NIH-124848 inhibited PI5P4Kγ + by
40 +− 3.2% with carrier-free (approximately 16 nM) ATP and
64 +− 2.8% with 100 μM ATP; the small shift in NIH-12848
sensitivity is probably an allosteric effect (see below).
To determine directly the interaction site of NIH-12848 with
PI5P4Kγ and PI5P4Kγ + , we turned to HDX–MS, a powerful
tool for mapping protein conformational changes and binding
epitope sites of interaction on proteins [21,25]. There are two
peptides in PI5P4Kγ whose rate of HDX is altered significantly in
the presence of NIH-12848 (Figures 3B–3D). One peptide spans
residues 373–407 (Figures 3C and 3D), part of the enzyme’s
activation loop, which has been shown to govern the substrate
specificity of PI5P4Ks and PI4P5Ks [26,27]. There was also
a change in a peptide spanning residues 158–162 (Figures 3C
and 3D), which is part of an α-helix that is near the activation
loop in PI5P4Kγ (PDB 2GK9), designated α-helix 4 in the
original annotated PI5P4Kβ structure [28] (Figures 3B and 3F).
Intriguingly, in the PI5P4Kγ + there was a significant increase
in exchange in residues 158–162 compared with WT PI5P4Kγ
and a correspondingly larger decrease in exchange upon addition
of NIH-12848 (Figure 3E). These data point to the proposed
PI5P-binding site of PI5P4Ks [26,27,28] as the likely area of
NIH-12848 interaction.
PI5P4Kγ can be made resistant to NIH-12848
Direct competition experiments (increasing PI5P and looking at
the effect that this has on NIH-12848 potency in vitro) would
be the most direct route to confirming the above suggestion.
However, NIH-12848 is a hydrophobic compound, as is PI5P
and it is likely that the two compounds would form mixed
micellar structures when together in aqueous buffers, so any such
‘competition’ would be uninterpretable. To seek confirmation
for the site of interaction of NIH-12848 we therefore undertook
Figure 4 Effect of inhibitor NIH-12848 on PI5P4Kγ harbouring a single
amino acid substitution
PI5P4Kγ mutant N165I was assayed in the presence of 0, 5 and 50 μM NIH-12848 and showed
no significant sensitivity towards this inhibitor. n = 3–6 replicates for each condition, error bars
represent +− S.E.M.
a series of mutational experiments, focusing on the regions of
interaction suggested by the HDX–MS data. In the region 373–
407 (see above), only Glu378 differs between PI4P5K isoforms and
mutating this residue to the PI5P4Kα equivalent histidine made no
detectable difference to the activity or NIH-12848 sensitivity of
the enzyme (result not shown). In residues 158–162 (see above),
Ile159 and Asp161 are both valines in PI5P4Ks α and β and mutating
these together in PI5P4Kγ + caused a small shift in sensitivity
to NIH-12848 [inhibition by 10 μM NIH-12848 was 96% +−
1.5 in WT PI5P4Kγ + and 71%+− 2.6 in the (E378H,I159V,D161V)
PI5P4Kγ + mutant].
Examining this region closely in the structure (Figure 3F)
suggested three other residues that might interact with the
substrate or inhibitor and which are different between PI5P4K
γ compared with α/β. These are Ser164, Asn165 and Glu153,
which are respectively asparagine, isoleucine and threonine
in PI5P4Kα/β; of these, Glu153 has already been mutated to
the PI5P4Kα/β-equivalent threonine in creating PI5P4Kγ +
[12]. We therefore introduced all five mutations of potential
interest (Q378H, I159V, D161V, S164N, N165I) into PI5P4Kγ and
PI5P4Kγ + and both these mutant enzymes were completely
resistant to NIH-12848 inhibition (Supplementary Figures S4A
and S4B).
These data support the HDX–MS data suggesting that NIH-
12848 is binding to this area of the PI5P4Kγ protein and they
also imply that Ser164 and/or Asn165 are the major contributors
to the sensitivity of PI5P4Kγ to NIH-12848. So we mutated
only those two residues in PI5P4Kγ to their PI5P4Ks α/β
homologues individually or together and found that whereas
S164N PI5P4Kγ is as sensitive to NIH-12848 inhibition as
WT PI5P4Kγ (Supplementary Figure S4C), N165I PI5P4Kγ
is completely insensitive, with 50 μM NIH-12848 having no
effect on this mutant (Figure 4). Note that the activity of N165I
(A) Global HDX of Apo PI5P4Kγ . (B) Structure of PI5P4Kγ with changes induced by 10 μM NIH-12848 shown in pseudo-colour. (C) Summary of changes induced by NIH-12848. (D) Kinetics of
HDX +− 10 μM NIH-12 848 in two regions of PI5P4Kγ . (E) Quantification of HDX in region of residues 158–162 in PI5P4Kγ and PI5P4Kγ + with or without NIH-12848. (F) Model of PI5P4Kγ
active site (PDB 2GK9) with residues mutated in the present study highlighted in red (note that the E153T mutation engineered in PI5P4Kγ + [12] is highlighted here in yellow, see text). The activation
loop (containing Gln378) is not visible in the X-ray structure and is a conjectural conformation, as is the location of the ATP and PI5P substrates. Also in yellow (but not indicated) are Asp374, which
is a conserved aspartate crucial for ATP binding [28] and Ala386, which dictates the substrate specificity of PI5P4Ks [26,27].
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Figure 5 Effects of NIH-12848 on mpkCCD cells
(A) Effect of 10 μM NIH-12848 on Na+ /K+ -ATPase α-1 localization. Cells were grown on glass coverslips at sub-confluence and then treated for 24 h with inhibitor or carrier (DMSO). They were
stained for ZO-1 (gap junctions; red) or Na+ /K+ -ATPase α-1 (green) and viewed under a confocal microscope. Low resolution imaging showed that > 90 % of the cells were as shown in these
higher resolution images and at least three experiments were performed with identical results. Objective 100×; scale bars = 10 μm. (B) Effect of 10 μM NIH-12848 on dome formation. Cells were
grown on plastic dishes to confluence (no domes present) (left) and then for a further 48 h with inhibitor or carrier (right). Phase contrast images of cell monolayers are shown. Objective 20×; scale
bars = 50 μm. (C) Effect of 10 μM NIH-12848 after domes have formed. Cells were grown on plastic dishes for 5 days to allow dome formation (left) and then with inhibitor or carrier for a further
24 h (right). Phase contrast images of cell monolayers are shown. Objective 20×; scale bars = 50 μm.
PI5P4Kγ was 6.7× higher than WT PI5P4Kγ in these assays
and Supplementary Figure S4(D) summarizes the activities and
sensitivities to NIH12848 of the mutants discussed in the present
study.
Overall, these data show that Asn165 is the residue in PI5P4Kγ
that is almost entirely responsible for its sensitivity to NIH-
12848. There was no detectable change in the amide exchange
rate at Asn165 when NIH-12848 binds to PI5P4Kγ or PI5P4Kγ +
(Figure 3) and the simplest interpretation is that NIH-12848 binds
to the activation loop and α-helix 4 to induce a change in the
structure in this region and that introducing an isoleucine (as in
PI5P4Ks α and β) at residue 165 prevents this structural change
from happening, perhaps because of a hydrophobic interaction
with the activation loop (Figure 3F). Whatever the molecular
mechanism, this residue could, in the future, be mutated in both
alleles of the PI5P4Kγ gene in a cell line or a mouse to engender
NIH-12848 resistance of the PI5P4Kγ , which would be a
powerful chemical biology approach to eliminate completely any
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Figure 6 Effect of RNAi Knock-down of PI5P4Kγ or mpkCCD cells
(A) Specificity and depletion efficiency of PI5P4Kγ siRNA. mpkCCD cells grown on plastic dishes were transfected with control siRNA or PI5P4Kγ -specific siRNA. After 72 h, the transfection
was repeated. After a further 48 h, RNA was extracted and the expression levels of each PI5P4K isoform was evaluated by reverse transcription quantitative PCR (RT-qPCR). Values (above)
are expressed as fold difference in knocked-down cells relative to control cells with TBP as the reference gene. Depletion of PI5P4Kγ was also evaluated in cell lysates by Western blot
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Table 1 mRNA levels of PI5P4Ks in mpkCCD cells grown to confluence
Gene PI5P4Kγ PI5P4Kα PI5P4Kβ
Polarized mpkCCD cells 3.19–3.46 0.99–1.01 0.51–0.53
The relative expression of the three genes PI5P4Kγ , α and β , with TBP as a reference
gene, was determined in a reverse transcription quantitative PCR (RT-qPCR) assay. Values are
expressed as fold difference in polarized cells (4 days after reaching confluence when domes
are formed) relative to pre-confluent cells (no domes present).
potential non-specific cellular effects of NIH-12848. Introducing
the complementary mutations into PI5P4Ks α or β, possibly to
make them NIH-12848-sensitive, could be an equally informative
avenue of investigation.
Effects of NIH-12848 on a kidney cell line
PI5P4Kγ is widely expressed in mammalian tissues, but is
particularly high and is indeed the principal PI5P4K isoform in
kidney [9]. It is expressed there in epithelial cells, particularly
in the thick ascending limb and CCD, so to explore its cellular
functions we chose mpkCCD cells, a cell line derived from
epithelial cells in the cortical collecting duct of the kidney
[22,23]. Western blotting confirmed an easily detectable level of
expression of PI5P4Kγ in mpkCCD cells (Figure 6A). These cells
grow to confluence and then form gap junctions between them.
They then begin to form ‘domes’ in which they show a property
of transporting epithelia when cultured in vitro on solid supports.
‘Domes’ are fluid-filled blisters formed between the solid growth
surface and the cell layer and their formation is regarded as a
sign of differentiated epithelia with active transport processes and
with an intact epithelial barrier due to functional cell–cell contacts
[22,23]. We found using quantitative PCR (QT-PCR) that while
reaching confluence there is a three-fold increase in PI5P4Kγ
mRNA, but no significant change in the two other PI5P4K
isoforms (Table 1). We thought that PI5P4Kγ might be involved
in epithelial cell polarity because in adult mammalian kidney
PI5P4Kγ is present in intracellular vesicles with a distribution
polarized towards the lumen [9] and in zebra fish (Danio) it is
highly expressed in the pro-nephric duct throughout development
(ZFIN Database: ZDB-IMAGE-030829-506).
One easily monitored parameter is the redistribution of
Na+ /K+ -ATPase from the cytoplasm to the basolateral plasma
membrane that occurs when the cells reach confluence [29]. We
explored the effect of 10 μM NIH-12848 (1 μM had similar
but smaller effects) and found a complete inhibition of this
redistribution, although the cells remained healthy and confluent,
with gap junctions formed as revealed by immunocytochemistry
of ZO-1 (Figure 5A). From this, we suggest PI5P4Kγ is involved
in the progress towards a polarized epithelial phenotype.
Consistent with this possibility, the formation of ‘domes’
(see above) was also markedly inhibited (Figure 5B) by NIH-
12848. Moreover, if NIH-12848 was added subsequent to
dome formation, the domes disappeared with a detectable
effect within 3 h that was maximal by 24 h (Figure 5B),
indicating a dynamic relationship between PI5P4Kγ and the
development and maintenance of this morphology. The molecular
mechanisms underlying this relationship will require much further
investigation, but the reported link between PI5P4Kγ and Rho
[11], taken together with the well-known involvement of Rho in
epithelial cell transport and polarity [30,31], offers one possibility
for exploration.
RNAi knockdown of PI5P4Kγ
Our extensive molecular exploration of the interaction of
NIH-12848 with PI5P4Kγ (above) emphasizes its remarkable
specificity, but nevertheless it is possible that the effects we see are
due to an off-target action. To gather some independent evidence
that inhibition of PI5P4Kγ underlies the effects of NIH-12848
and thus to begin a validation of this inhibitor as a tool for
exploring PI5P4Kγ function, we knocked down PI5P4Kγ in the
mpkCCD cells by RNAi. Figure 6(A) and Supplementary Table
S3 shows that the knockdown was specific and successful and
Figures 6(B) and 6(C) show the effects of PI5P4Kγ knockdown on
Na+ /K+ -ATPase re-localization (Figure 6B) and dome formation
(Figure 6C). Within the limits of these analyses, both effects of
NIH-12848 are mimicked by this knockdown.
Control experiments knocking down PI5P4Kα and β did not
show the same effect on dome formation. PI5P4Kβ knockdown
had no detectable effect (Supplementary Figure S5B), whereas
knockdown of PI5P4Kα had a pronounced opposite (stimulatory)
effect (Supplementary Figures S5A and S4B). We have no
immediate explanation for this latter action, which we believe is
likely to be independent of PI5P4Kγ activity because knockdown
of PI5P4Kγ and PI5P4Kα together showed that PI5P4Kγ causes
a similar and internally consistent inhibitory effect on the higher
level of dome formation resulting from PI5P4Kα knockdown
(Supplementary Figure S5C). Further studies, including using
PI5P4Kα inhibitors (e.g. [15]) will be required to clarify this
function of PI5P4Kα and its relationship with PI5P4Kγ . We
have discussed elsewhere [12] the possibility that PI5P4Kγ may
sometimes serve to target the more active PI5P4Kα to a specific
cellular location.
Overall, these experiments yield the first functional insight into
PI5P4Kγ ’s physiological role in epithelial cells. Much remains
to be explored to clarify exactly what the enzyme is doing in this
context, but the very similar effects induced in mpkCCD cells
by inhibition with NIH-12848 and knockdown of PI5P4Kγ are a
crucial first stage in a proof of principle of the potential usefulness
of NIH-12848 in such an exploration. Our detailed mapping and
manipulation of the molecular interaction of NIH-12848 with
PI5P4Kγ also suggests ways to a wider use of this inhibitor in
the exploration of functions of the PI5P4K family.
(below). Equal volumes of cell lysates were loaded on a SDS/PAGE (10 % gel) and PI5P4Kγ was detected with an isoform-specific polyclonal antibody (see Materials and Methods). (B) Effect of
siRNA knockdown of PI5P4Kγ on Na+ /K+ -ATPase α-1 localization. Cells grown on glass coverslips were depleted of endogenous PI5P4Kγ by siRNA as described in ‘Material and Methods’.
Confocal sections of cells fixed and stained for Na+ /K+ -ATPase α-1 (green) and ZO-1 (red) are shown. These images are typical of two independent experiments and the images are representative
of > 90 % of cells examined. Objective 63×; scale bars = 10 μm. (C) Effect of siRNA knockdown of PI5P4Kγ on dome formation. mpkCCD cells grown on plastic dishes were depleted of
endogenous PI5P4Kγ by siRNA as described in ‘Material and Methods’. Phase contrast images of cell monolayers are shown. Objective 10×; scale bars = 50 μm. (D) Surface density of cell domes
was measured in mpkCCD confluent cell monolayers that were transfected with PI5P4Kγ -specific siRNA or only transfection reagent (control 2) or non-target oligos siRNA (control 3). In control 1,
cells were not transfected. Values are expressed as means +− S.E.M. *P < 0.001 compared with control 3. Significant differences were analysed by Student’s t test; Nr, number.
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